Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration.
Affiliation
CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.Issue Date
2002-03
Metadata
Show full item recordAbstract
Platinum-based combination and single-agent chemotherapy have become accepted as treatments for locally advanced and metastatic nonsmall cell lung cancer as a consequence of improved survival, quality of life, and symptom control compared with best supportive care. However, it is clear that a therapeutic plateau has been reached with current combinations requiring a re-evaluation of strategies to improve clinical outcomes. Dose intensification may offer one way in which to achieve better results, as may extension of the duration of treatment. The evidence suggests that dose intensification is a useful tool, and that its use in combination with markers of treatment duration and cumulative dose may help to maximize results from current active drug combinations.Citation
Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration. 2002, 14 (2):191-8 Curr Opin OncolJournal
Current Opinion in OncologyPubMed ID
11880710Type
ArticleLanguage
enISSN
1040-8746Collections
Related articles
- Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival.
- Authors: Lilenbaum RC, Langenberg P, Dickersin K
- Issue date: 1998 Jan 1
- Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms.
- Authors: Socinski MA
- Issue date: 2004 Jun 15
- [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
- Authors: Langer F, Helsberg K, Schütte WH, Leschinger MI
- Issue date: 2005 Mar
- Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
- Authors: Chu Q, Vincent M, Logan D, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care
- Issue date: 2005 Dec
- First- and second-line therapy for advanced nonsmall cell lung cancer.
- Authors: Sculier JP, Moro-Sibilot D
- Issue date: 2009 Apr